No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 11.6x · 10Y median 12.4x · 41st percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T19:58:38.292Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Pyxis Oncology, Inc. (PYXS) stock was $2.02 as of Oct 6, 2026, 3:55 PM EDT, down 10.04% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -12.8% · 3-year avg +3.7%/yr
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer.
Biotechnology · Boston, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 2, 2026
27 days away
EPS Estimate
-0.27
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.40
vs Estimate
$-0.35
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PYXS | $127.66M | $2.02 | -10.04% | -12.78% | N/A | N/A | N/A |
| 2NRXP | $128.37M | $2.96 | +3.31% | -12.18% | -49.61% | N/A | vs PYXS |
| 3ENTX | $125.44M | $2.54 | -2.86% | +37.68% | -10.57% | N/A | vs PYXS |
| 4HCAT | $130.79M | $1.77 | +0.57% | -40.39% | -48.35% | N/A | vs PYXS |
| 5HURA | $124.50M | $1.96 | +4.55% | -27.96% | -45.49% | -52.09% | vs PYXS |
| 6AIRS | $130.86M | $1.85 | -2.88% | -75.16% | N/A | N/A | vs PYXS |
forward FY estimate
N/A
$0.00
vs Estimate
$33333.00
Consensus Rating
Based on 9 analysts
Average Price Target
$8.67
+330.1% upside
Low
$6.00
Current
$2.02
High
$19.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.32 | $-0.28 | $-0.26 | 6 |
| Quarter ending Dec 2026 | $-0.31 | $-0.26 | $-0.20 | 6 |
| Quarter ending Mar 2027 | $-0.24 | $-0.24 | $-0.24 | 2 |
| Quarter ending Jun 2027 | $-0.25 | $-0.25 | $-0.25 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.37 | $-1.22 | $-1.09 | 6 |
| FY 2027 | $-1.57 | $-1.13 | $-0.75 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $25000.00 | $25000.00 | $25000.00 | 9 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $21875.00 | $21875.00 | $21875.00 | 9 |
| FY 2027 | $3.13M | $3.13M | $3.13M | 9 |
